An integrated reactive metabolite evaluation approach to assess and reduce safety risk during drug discovery and development

Chemico-Biological Interactions

Volumn 192, Issue 1-2, 2011, Pages 60-64

  Reese, Melinda ^a   Sakatis, Melanie ^b   Ambroso, Jeffrey ^a   Harrell, Andrew ^b   Yang, Eric ^a   Chen, Liangfu ^a   Taylor, Maxine ^b   Baines, Ian ^b   Zhu, Lei ^a   Ayrton, Andy ^b   Clarke, Stephen ^b  

^a GLAXOSMITHKLINE   (United States)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Bioactivation; Covalent binding; Glutathione; Hepatotoxicity; Idiosyncratic; P450; Reactive metabolite

Indexed keywords

CYTOCHROME P450; DRUG METABOLITE; GLUTATHIONE; SKATOLE;

ANIMAL TISSUE; CONFERENCE PAPER; CONTROLLED STUDY; COVALENT BOND; DRUG ACTIVATION; DRUG METABOLISM; DRUG RESEARCH; DRUG SAFETY; HUMAN; HUMAN CELL; IC 50; LIVER MICROSOME; LIVER TOXICITY; NONHUMAN; RAT; RISK ASSESSMENT; RISK REDUCTION;

DRUG DISCOVERY; HUMANS; LIVER; SAFETY;

RATTUS;

EID: 79958063692     PISSN: 00092797     EISSN: 18727786     Source Type: Journal    
DOI: 10.1016/j.cbi.2010.10.005     Document Type: Conference Paper

References (19)

1. O.M. Bakke, M. Manacchia, F. De Abajo, K.I. Kaitin, and L. Lasagna Drug safety discontinuations in the United Kingdom, the United States, and Spain from 1974 through 1993. A regulatory perspective Clin. Pharmacol. Ther. 58 1995 108 117
2. R.A. Wilke, D. Lin, D. Roden, P. Watkins, D. Flockhart, I. Zineh, K. Giacomini, and R. Krauss Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges Nat. Rev. Drug Discov. 6 2007 904 916 (Pubitemid 350042398)
3. H. Motohashi, and M. Yamamoto Nrf2-Keap1 defines a physiologically important stress response mechanism Trends Mol. Med. 10 2004 549 557 (Pubitemid 39433824)
4. L.M. Aleksunes, and J.E. Manautou Emerging role of Nrf2 in protecting against hepatic and gastrointestinal disease Toxicol. Pathol. 35 2007 459 473 (Pubitemid 46911886)
5. T.W. Kensler, N. Wakabayashi, and S. Biswal Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway Annu. Rev. Pharmacol. Toxicol. 47 2007 89 116
6. J. Uetrecht Idiosyncratic drug reactions: current understanding Annu. Rev. Pharmacol. Toxicol. 47 2007 513 539
7. A.S. Kalguktar, I. Gardner, R.S. Obach, C.L. Shaffer, E. Callegari, K.R. Henne, A.E. Mutlib, D.K. Dalvie, J.S. Lee, Y. Nakai, J.P. O'Donnell, J. Boer, and S.P. Harriman A comprehensive listing of bioactivation pathways of organic functional groups Curr. Drug Metab. 6 2005 161 225 (Pubitemid 40753853)
8. C. Lammert, S. Einarsson, C. Saha, A. Niklasson, E. Bjornsson, and N. Chalasani Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals Hepatology 47 2008 2003 2009 (Pubitemid 351945567)
9. M.I. Lucena, R.J. Andrade, N. Kaplowitz, M. Garcia-Cortes, M.C. Fernández, M. Romero-Gomez, M. Bruguera, H. Hallal, M. Robles-Diaz, J.F. Rodriguez-González, J.M. Navarro, J. Salmeron, P. Martinez-Odriozola, R. Pérez-Alvarez, Y. Borraz, and R. Hidalgo Phenotypic characterization of idiosyncratic drug-induced liver injury: the influence of age and gender Hepatology 49 2009 2001 2009
10. C. Lammert, E. Bjornsson, A. Niklasson, and N. Chalasani Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events Hepatology 51 2 2010 615 620
11. M. Biour, R. Poupon, J.D. Grange, and O. Chazouilleres Hepatotoxicity of drugs Gastroenterol. Clin. Biol. 24 2000 1052 1091
12. Physicians' Desk Reference 57th ed. 2003 Thomson Corporation
13. S. Nakayama, R. Atsumi, H. Takakusa, Y. Kobayashi, A. Kurihara, Y. Nagai, D. Nakai, and O. Okazaki A zone classification system for risk assessment of idiosyncratic drug toxicity using daily dose and covalent binding Drug Metab. Dispos. 37 2009 1970 1977
14. T. Usui, M. Mise, T. Hashizume, M. Yabuki, and S. Komuro Evaluation of the potential of drug-induced liver injury based on in vitro covalent binding to human liver protein Drug Metab. Disp. 37 2009 2383 2392
15. R.S. Obach, A. Kalgutkar, J. Soglia, and S. Zhao Can in vitro metabolism-dependent covalent binding data in liver microsomes distinguish hepatotoxic from nonhepatotoxic drugs? an analysis of 18 drugs with consideration of intrinsic clearance and daily dose Chem. Res. Toxicol. 21 2008 1814 1822
16. D.C. Evans, A.P. Watt, D.A. Nicoll-Griffith, and T.A. Baillie Drug-protein adducts: an industry perspective on minimizing the potential for drug bioactivation in drug discovery and development Chem. Res. Toxicol. 17 2004 3 16 (Pubitemid 38134055)
17. R.K. Thimmulappa, K.H. Mai, S. Srisuma, T.W. Kensler, M. Yamamoto, and S. Biswal Identification of Nrf2-regulated genes induced by the chemopreventive agent sulforaphane by oligonucleotide microarray Cancer Res. 62 2002 5196 5203 (Pubitemid 35033454)
18. J.M. Lee, M.J. Calkins, K. Chan, Y.W. Kan, and J.A. Johnson Identification of the NF-E2-related Factor-2-dependent genes conferring protection against oxidative stress in primary cortical astrocytes using oligonucleotide microarray analysis J. Biol. Chem. 278 14 2003 12029 12038 (Pubitemid 36800179)
19. J. Gan, R. Qian, H. Bing, Z. Mingshe, and C.S. Wen In vitro screening of 50 highly prescribed drugs for thiol adduct formation - comparison of potential for drug-induced toxicity and extent of adduct formation Chem. Res. Toxicol. 22 2009 690 698